Paul Moraviec (born April 1958)[1] is a British businessman. He was the chief executive officer (CEO) of Convatec, an international medical products and technologies company, listed on the FTSE 100 Index, from April 2015 to October 2018.[2]
Paul Moraviec | |
|---|---|
| Born | April 1958 (age 66) |
| Nationality | British |
| Education | Kingston University |
| Occupation | Businessman |
| Title | CEO, Convatec |
| Term | April 2015-October 2018 |
Early life
editMoraviec has a master's degree in marketing from London's Kingston University Business School.[3]
Career
editBefore joining Convatec, he was vice president, neurosurgery business at Johnson & Johnson, and vice president, international commercialoperations at Abbott Laboratories.[4]
Convatec announced that Moraviec will be retiring with immediate effect on 15 October 2018, and will be succeeded on an interim basis by non-executive director Rick Anderson, who was formerly the chairman of Johnson & Johnson.[5]
References
edit- ^ "Paul MORAVIEC - Personal Appointments (free information from Companies House)". Beta.companieshouse.gov.uk. Retrieved 18 December 2016.
- ^ "ConvaTec Appoints Paul Moraviec CEO Effective April 30, 2015". Convatec.co.uk. 30 April 2015. Retrieved 18 December 2016.
- ^ Paul Moraviec (22 December 2014). "Paul Moraviec: Executive Profile & Biography". Bloomberg. Retrieved 18 December 2016.
- ^ "Paul Moraviec". The Wall Street Journal.
- ^ "Paul Moraviec". Convatec.
 | This United Kingdom business-related biographical article is a stub. You can help Wikipedia by expanding it. |